Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Mesenchymal stem cells after acute myocardial infarction.

- candidate number4608
- NTR NumberNTR1553
- ISRCTNISRCTN wordt niet meer aangevraagd
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR26-nov-2008
- Secondary IDsP.05.179 
- Public TitleMesenchymal stem cells after acute myocardial infarction.
- Scientific TitleAutologous bone marrow-derived in vitro expanded mesenchymal stem cell transplantation in patients with an acute myocardial infarction treated by successful primary percutaneous transluminal coronary angioplasty A safety and feasibility study
- hypothesisIntramyocardial injection of autologous mesenchymal stem cell injection after myocardial infarction may enhance recovery of myocardial function by stimulation of angiogenesis or regeneration of cardiomyocytes.
- Healt Condition(s) or Problem(s) studiedAcute myocardial infarction , Mesenchymal stem cells
- Inclusion criteria1. Acute ST segment elevation myocardial infarction treated by successful primary PTCA of the infarct related coronary artery within 12 hours after onset of chest pain
2. Increase in CPK levels >1600 U/L
3. Male or female >18 years old
4. Able and willing to undergo all the tests used in the protocol
5. Written informed consent
- Exclusion criteria1. Previous myocardial infarction or CABG
2. Evidence of cancer (except low grade and fully resolved non-melanoma skin malignancy)
3. Concurrent participation in a study using an experimental drug or an experimental procedure within 2 months before acute myocardial infarction
4. Unstable medical situation e.g. life-threatening heart failure
5. Other severe concurrent illnesses (e.g. active infection, aortic stenosis, renal failure)
6. Bleeding diathesis or HIV infection
7. Any other condition that, in the opinion of the investigator, could pose a significant threat to the subject if the investigational therapy was to be initiated
8. Candidates for additional surgical or percutaneous intervention within the study period
- mec approval receivedyes
- multicenter trialno
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-jan-2006
- planned closingdate31-dec-2009
- Target number of participants48
- Interventions- Bone marrow cell aspiration from the iliac crest
- Ex-vivo expansion of mesenchymal stem cells
- Intramyocardial injection (by catheterization) of expanded mesenchymal stem cells
- Primary outcome- Safety and feasibility of intramyocardial injection of ex vivo expanded mesenchymal stem cells after primary PTCA for acute myocardial infarction
- Secondary outcome- To assess the efficacy of autologous bone marrow-derived in vitro expanded mesenchymal stem cell transplantation after successful primary PTCA for acute myocardial infarction:
- Infarct size assessed by gated SPECT (baseline vs. 3 months)
- Left ventricular ejection fraction, left ventricular end-diastolic volume and left ventricular end-systolic volume as assessed by gated SPECT (baseline vs. 3 months)
- TimepointsBaseline and 3 months follow-up.
- Trial web siteN/A
- statusopen: patient inclusion
- Sponsor/Initiator Leiden University Medical Center (LUMC), Department of Cardiology
- Funding
(Source(s) of Monetary or Material Support)
Leiden University Medical Center (LUMC)
- PublicationsN/A
- Brief summaryRecently, stem cell transplantation has been proposed to serve as a novel therapeutic option in patients with acute myocardial infarction. In experimental studies, stem cell application to infarcted myocardium led to a decrease in infarct size, a decrease in apoptosis, a positive effect on left ventricular remodeling, increased contractile performance and an increase in survival of mice with experimental myocardial infarction. In the clinical setting, several randomized trials have been conducted which investigated the effect of intracoronary bone marrow-derived mononuclear cell injection. However, scarce data are available with regard to ex-vivo expanded mesenchymal stem cells. This study investigates the safety and feasibility of intramyocardial injection of ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells in patients with myocardial infarction. Therefore, bone marrow aspiration will be performed 2-3 days after myocardial infarction, and cultured mesenchymal stem cells will be injected in the myocardium with an injection catheter (NOGA system). Safety will be monitored using holter registrations, laboratory measurements and clinical follow-up. Furthermore, effects on cardiac perfusion and function will be assessed with the us of echocardiography and gated-SPECT.
- Main changes (audit trail)
- RECORD26-nov-2008 - 2-dec-2008

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar